## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.0% below STRENGTH zone (3.0-6.0%); PEG 1.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($169.98)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?**
- Source: TradingView â€” Track All Markets | 20251224T140823 | Somewhat-Bullish | Relevance: 100%
- Quest Diagnostics (DGX) is considered a good investment due to strategic acquisitions, advanced diagnostics, and cost management. However, concerns exist regarding its debt levels and macroeconomic challenges. The company has shown strong earnings performance, beating estimates consistently.

**2. Quest Diagnostics Incorporated $DGX Shares Sold by Coho Partners Ltd.**
- Source: MarketBeat | 20251223T200820 | Neutral | Relevance: 100%
- Coho Partners Ltd. significantly reduced its stake in Quest Diagnostics (NYSE:DGX) by 42.3% in Q3, selling 65,380 shares and retaining 89,103 shares, making DGX its 26th largest holding. Despite this, other institutional investors have increased their positions. Quest Diagnostics beat Q3 earnings estimates with $2.60 EPS and revenue of $2.82 billion, and expects FY2025 EPS between $9.76 and $9.84, while announcing a quarterly dividend of $0.80 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 6 ($3.55M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 16.9x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 16.9 |
| Current P/E | 17.9 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.2% to -3.0% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.0pp (needs >3.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.75), momentum weakening. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.03% (CS: 12) | Weak |
| RSI_14 | 37.6 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 0.962x | Below |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $175.82
- **Stop Loss:** $169.98 (3.3% risk)
- **Target:** $181.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 205
- **Position Value:** $36,043.10
- **Portfolio %:** 36.04%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*